Asked by Leo
Pharmacogenic testing can provide what information in the Healthcare setting?
All Answers 1
Answered by
GPT-5 mini
AI
Pharmacogenetic (pharmacogenomic) testing analyzes a person’s genetic variants to predict how they will respond to certain medicines. In clinical practice it can provide the following information:
- Metabolizer phenotype: predicts enzyme activity (e.g., poor, intermediate, normal/normal-rapid, ultrarapid) for drug‑metabolizing enzymes such as CYP2D6, CYP2C19, CYP2C9.
- Likely drug efficacy: whether a patient is more or less likely to benefit from a specific drug (e.g., clopidogrel and CYP2C19).
- Risk of adverse drug reactions or toxicity: identifies genetic risks that increase chance of serious toxicity (e.g., DPYD variants → fluoropyrimidine toxicity; TPMT/NUDT15 → thiopurine toxicity; HLA-B*57:01 → abacavir hypersensitivity).
- Dosing guidance: provides genotype-informed dose adjustments or selection of alternative drugs (e.g., warfarin—CYP2C9/VKORC1 guidance; codeine—CYP2D6).
- Drug selection or avoidance: recommends choosing an alternative drug when genetics predicts poor response or high risk (e.g., avoid carbamazepine with HLA-B*15:02 in susceptible populations).
- Identification of drug–gene and drug–drug–gene interactions: helps interpret combined effects of genetics and co-medications on drug levels/effects.
- Actionable clinical recommendations: many reports map genotypes to CPIC/Dutch Pharmacogenetics Working Group or FDA recommendations used in prescribing.
Limitations to keep in mind:
- Not all drugs have useful genetic predictors; genetics is only one factor (age, liver/kidney function, comorbidity, drug interactions, adherence also matter).
- Panels vary in which genes/variants they test; negative result does not guarantee normal response.
- Interpretation requires clinical context and sometimes specialist/pharmacist input.
When useful:
- Before starting drugs with known pharmacogenetic impact (antiplatelets, anticoagulants, some antidepressants/antipsychotics, analgesics, oncology agents, immunosuppressants), or after unexplained treatment failure or adverse reactions.
For clinical use, results are best reviewed with the prescribing clinician or a pharmacogenomics-literate pharmacist and referenced against guidelines such as CPIC and FDA labeling.
- Metabolizer phenotype: predicts enzyme activity (e.g., poor, intermediate, normal/normal-rapid, ultrarapid) for drug‑metabolizing enzymes such as CYP2D6, CYP2C19, CYP2C9.
- Likely drug efficacy: whether a patient is more or less likely to benefit from a specific drug (e.g., clopidogrel and CYP2C19).
- Risk of adverse drug reactions or toxicity: identifies genetic risks that increase chance of serious toxicity (e.g., DPYD variants → fluoropyrimidine toxicity; TPMT/NUDT15 → thiopurine toxicity; HLA-B*57:01 → abacavir hypersensitivity).
- Dosing guidance: provides genotype-informed dose adjustments or selection of alternative drugs (e.g., warfarin—CYP2C9/VKORC1 guidance; codeine—CYP2D6).
- Drug selection or avoidance: recommends choosing an alternative drug when genetics predicts poor response or high risk (e.g., avoid carbamazepine with HLA-B*15:02 in susceptible populations).
- Identification of drug–gene and drug–drug–gene interactions: helps interpret combined effects of genetics and co-medications on drug levels/effects.
- Actionable clinical recommendations: many reports map genotypes to CPIC/Dutch Pharmacogenetics Working Group or FDA recommendations used in prescribing.
Limitations to keep in mind:
- Not all drugs have useful genetic predictors; genetics is only one factor (age, liver/kidney function, comorbidity, drug interactions, adherence also matter).
- Panels vary in which genes/variants they test; negative result does not guarantee normal response.
- Interpretation requires clinical context and sometimes specialist/pharmacist input.
When useful:
- Before starting drugs with known pharmacogenetic impact (antiplatelets, anticoagulants, some antidepressants/antipsychotics, analgesics, oncology agents, immunosuppressants), or after unexplained treatment failure or adverse reactions.
For clinical use, results are best reviewed with the prescribing clinician or a pharmacogenomics-literate pharmacist and referenced against guidelines such as CPIC and FDA labeling.
Submit Your Answer
We prioritize human answers over AI answers.
If you are human, and you can answer this question, please submit your answer.